Literature DB >> 20832500

The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.

Jia Liu1, Sonia Wennier, Grant McFadden.   

Abstract

Myxoma virus (MYXV) is a poxvirus with a strict rabbit-specific host-tropism for pathogenesis. The immunoregulatory factors encoded by MYXV can suppress some functions of immune effectors from other species. We review their mechanisms of action, implications in therapeutics and the potential to improve MYXV as an oncolytic agent in humans.
Copyright © 2010 Institut Pasteur. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20832500      PMCID： PMC2998584          DOI： 10.1016/j.micinf.2010.08.012

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  74 in total

1.  The complete DNA sequence of myxoma virus.

Authors:  C Cameron; S Hota-Mitchell; L Chen; J Barrett; J X Cao; C Macaulay; D Willer; D Evans; G McFadden
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

2.  A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

Authors:  A Bowie; E Kiss-Toth; J A Symons; G L Smith; S K Dower; L A O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

Review 3.  Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus.

Authors:  Masmudur M Rahman; Gerard J Madlambayan; Christopher R Cogle; Grant McFadden
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-07       Impact factor: 7.638

4.  Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells.

Authors:  John W Barrett; Chew Shun Chang; Gen Wang; Steven J Werden; Zhuhong Shao; Catherine Barrett; Xiujuan Gao; Tara A Belsito; Danielle Villenevue; Grant McFadden
Journal:  Virology       Date:  2006-12-20       Impact factor: 3.616

5.  A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history.

Authors:  José M González; Mariano Esteban
Journal:  Virol J       Date:  2010-03-15       Impact factor: 4.099

6.  The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury.

Authors:  L Liu; A Lalani; E Dai; B Seet; C Macauley; R Singh; L Fan; G McFadden; A Lucas
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 7.  Toll-like receptor signaling in cell proliferation and survival.

Authors:  Xinyan Li; Song Jiang; Richard I Tapping
Journal:  Cytokine       Date:  2009-09-22       Impact factor: 3.861

8.  Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection.

Authors:  Erbin Dai; Li-Ying Liu; Hao Wang; Dana McIvor; Yun Ming Sun; Colin Macaulay; Elaine King; Ganesh Munuswamy-Ramanujam; Mee Yong Bartee; Jennifer Williams; Jennifer Davids; Israel Charo; Grant McFadden; Jeffrey D Esko; Alexandra R Lucas
Journal:  PLoS One       Date:  2010-05-06       Impact factor: 3.240

9.  Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.

Authors:  XueQing Lun; Tommy Alain; Franz J Zemp; Hongyuan Zhou; Masmudur M Rahman; Mark G Hamilton; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

10.  Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells.

Authors:  M Kim; G J Madlambayan; M M Rahman; S E Smallwood; A M Meacham; K Hosaka; E W Scott; C R Cogle; G McFadden
Journal:  Leukemia       Date:  2009-10-29       Impact factor: 11.528
View more
  20 in total

1.  Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.

Authors:  Masmudur M Rahman; Grant McFadden
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Oncolytic Poxviruses.

Authors:  Winnie M Chan; Grant McFadden
Journal:  Annu Rev Virol       Date:  2014-09-01       Impact factor: 10.431

3.  Myxoma virus M064 is a novel member of the poxvirus C7L superfamily of host range factors that controls the kinetics of myxomatosis in European rabbits.

Authors:  Jia Liu; Sonia Wennier; Nissin Moussatche; Mary Reinhard; Richard Condit; Grant McFadden
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 4.  An overview of the lagomorph immune system and its genetic diversity.

Authors:  Ana Pinheiro; Fabiana Neves; Ana Lemos de Matos; Joana Abrantes; Wessel van der Loo; Rose Mage; Pedro José Esteves
Journal:  Immunogenetics       Date:  2015-09-23       Impact factor: 2.846

5.  Comparative analysis of poxvirus orthologues of the vaccinia virus E3 protein: modulation of protein kinase R activity, cytokine responses, and virus pathogenicity.

Authors:  Chad Myskiw; Janilyn Arsenio; Craig Hammett; Rebekah van Bruggen; Yvon Deschambault; Nicole Beausoleil; Shawn Babiuk; Jingxin Cao
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

6.  Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation.

Authors:  Cristhian J Ildefonso; Henrique Jaime; Masmudur M Rahman; Qiuhong Li; Shannon E Boye; William W Hauswirth; Alexandra R Lucas; Grant McFadden; Alfred S Lewin
Journal:  Hum Gene Ther       Date:  2015-01       Impact factor: 5.695

7.  Myxoma and vaccinia viruses bind differentially to human leukocytes.

Authors:  Winnie M Chan; Eric C Bartee; Jan S Moreb; Ken Dower; John H Connor; Grant McFadden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.

Authors:  Steven J Conrad; Jia Liu
Journal:  Methods Mol Biol       Date:  2019

Review 9.  Cytokine synergy: an underappreciated contributor to innate anti-viral immunity.

Authors:  Eric Bartee; Grant McFadden
Journal:  Cytokine       Date:  2013-05-18       Impact factor: 3.861

Review 10.  Oncolytic myxoma virus: the path to clinic.

Authors:  Winnie M Chan; Masmudur M Rahman; Grant McFadden
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.